Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Open accessThe DOI matches its Crossref record; 162 of the 167 references it cites were found in a registry or an index; 110 of the 165 sources its claims cite were checked for support.
Abstract
The innovative development of nanomedicine has promised effective treatment options compared to the standard therapeutics for cancer therapy. However, the efficiency of EPR-targeted nanodrugs is not always pleasing as it is strongly prejudiced by the heterogeneity of the enhanced permeability and retention effect (EPR). Targeting the dynamics of the EPR effect and improvement of the therapeutic effects of nanotherapeutics by using EPR enhancers is a vital approach to developing cancer therapy. Inadequate data on the efficacy of EPR in humans hampers the clinical translation of cancer drugs. Molecular targeting, physical amendment, or physiological renovation of the tumor microenvironment (TME) are crucial approaches for improving the EPR effect. Advanced imaging technologies for the visualization of EPR-induced nanomedicine distribution in tumors, and the use of better animal models, are necessary to enhance the EPR effect. This review discusses strategies to enhance EPR effect-based drug delivery approaches for cancer therapy and imaging technologies for the diagnosis of EPR effects. The effort of studying the EPR effect is beneficial, as some of the advanced nanomedicine-based EPR-enhancing approaches are currently undergoing clinical trials, which may be helpful to improve EPR-induced drug delivery and translation to clinics.
Overview
CoChat Summary
## TL;DR
This review argues that EPR-based nanodrug delivery is promising but highly variable in humans because tumor vasculature, extracellular matrix, and the tumor microenvironment are heterogeneous. It surveys pharmacological, physical, and imaging-based strategies to improve EPR and emphasizes that personalized, model-appropriate, multimodal approaches are needed for clinical translation.
## Key findings
- The paper identifies two broad classes of EPR-enhancing strategies: pharmacological approaches that alter the tumor microenvironment, and physical approaches using external stimuli such as heat, radiation, photodynamic therapy, and ultrasound.
- It reports several quantitative examples from prior studies: tissue plasminogen activator pretreatment increased penetration of 115 nm nanoparticles in A549 xenograft mice; DC101 plus chemotherapy produced an approximately threefold accumulation increase of smaller nanoparticles; a cediranib plus size-changeable gold nanoparticle strategy produced about a twofold increase in tumor size suppression; liposomal doxorubicin plus NaHCO3 increased drug uptake by 21-fold in a TNBC mouse model.
- The review cites literature estimating that only 0.7% of systemically administered nanoparticles reach tumors, and that only 0.1% to 0.2% of the injected dose is effective against tumor cells with significant anticancer effects.
- It highlights a major controversy: one cited study found that around 97% of nanoparticles may enter tumors via active transcytosis rather than passive transport through endothelial gaps.
## Methods
- This is a narrative review of published work on EPR-based drug delivery for cancer therapy and diagnosis, organized around strategies to enhance EPR, tumor microenvironment targeting, imaging, challenges, and clinical translation.
- The paper synthesizes evidence from preclinical animal models, some clinical studies, and imaging studies, and discusses specific examples of nanoparticles, drugs, and EPR enhancers reported in the literature.
- Its main analysis is comparative and conceptual rather than experimental: it classifies strategies, summarizes reported outcomes, and argues for multimodal imaging and better animal models to evaluate EPR more accurately.
## Limitations
- The paper explicitly states that data on the efficacy of EPR in humans are inadequate, which hampers clinical translation.
- It also states that EPR is highly heterogeneous across tumor types, sizes, sites, and patients, so one-size-fits-all approaches are inadequate.
- Evident from the text: the paper is a review and does not present original experimental data, so its conclusions depend on the quality and consistency of the cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Pharmacological approaches to improve EPR effect. (A). Vascular normalizer to improve the blood flow, (B). Fibrinolytics co-therapy, (C). Enhanced permeability of endothelial cells using vascular mediators, (D). Stromal density decreases by ECM degradation, (E). Tumor-penetrating peptides enhance transcytosis. Reprinted with permission from [23]. Copyright (2023), with permission from Elsevier.](https://figures.cochat.ai/paper-figures/d8d57d6e81b946b5aac7f395fbf5f7ca/approaches-to-improve-epr-based-drug-delivery-for-cancer-therapy-and-diagnosis-figure-1.jpg)
![Figure 2 Strategies to enhance EPR-based drug delivery targeting the tumor microenvironment. Adapted with permission from [17].](https://figures.cochat.ai/paper-figures/6ea3df71c40a4cc0967de3efe05abf30/approaches-to-improve-epr-based-drug-delivery-for-cancer-therapy-and-diagnosis-figure-2.jpg)
![Figure 3 Imaging NP pharmacology and the EPR effect across multiple spatial and temporal scales. (A) Pharmacokinetics and pharmacodynamics (PK/PD) of NPs (B). Imaging strategies and (C) IVM modalities are particularly suitable for imagining dynamic and microscopic courses of the EPR effect and the TME. Adapted with permission from [18].](https://figures.cochat.ai/paper-figures/f1710454586346b5b4ef8dabd7eb4ef5/approaches-to-improve-epr-based-drug-delivery-for-cancer-therapy-and-diagnosis-figure-3.jpg)
Verification
Claims the paper makes
76 Valid · 10 Not valid · 36 Not checked · 33 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In clinical settings, this approach has been proven to be ineffective when used alone [23].”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 2. Major Advances and Emerging Concepts of EPR-Enhancing Strategies > 2.2. Normalization of Vasculature One of the classical approaches is to administer antiangiogenic compounds and deprive the tumor tissue of oxygen and nutrients. In clinical settings, this approach has been proven to be ineffective when used alone [23]. Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment. An intermediate dose of anti-VEGF receptor two antibodies (DC101) was used to successfully normalize the blood vasculature in and around the tumor site, thereby reducing the necrotic and hypoxic regions [25]. Further, the research group administered a combination of Doxil (around 125 nm in size) or Abaxane (around 12 nm in size) in breast tumor-bearing mice and observed a significant (around threefold) accumulation of smaller nanoparticles [26]. This concludes the DC101 improved tumor vascular normalization leading to a smaller and homogenous pore on the tumor vessel wall [25]. Another class of drugs used to aid in vascular normalization is tyrosine kinase inhibitors (TKIs), a small molecule class of drugs. Several research groups employed treatment with erlotinib, an EPR enhancer which is a TKI against epidermal growth factor receptor (EGFR). This improved the accumulation of human serum albumin-bound paclitaxel (HAS-PTX) in vivo in tumor-bearing mice such as head and neck carcinoma cells (SCC7), colon carcinoma cells (CT26), and breast cancer cells (4T1) [27]. A significant tumor size reduction was observed in models with combination therapy of erlotinib and has-PTX in comparison to the HAS-PTX group alone. A higher vascular normalization resulted in a higher distribution of hasHSA-PTX to the tumor site. Another TKI, Imatinib, inhibits VEGF-independent angiogenesis and also improves the delivery of nanoparticles to the tumor site, which was observed in A459 xenograft tumor models (lung carcinoma) [28]. Most research groups have reported that vascular normalization results in pore size reduction in the tumor vasculature. One of the problems with vascular normalization is the accumulation and quick clearance of small-sized nanoparticles. Research groups such as Xiao et al. used a combination of cediranib (VEGFR TKI) and enzyme-responsive size changeable gold nanoparticles (from around 40 nm to 300 nm upon enzymatic activity) [29]. The size-changeable gold nanoparticles have shown an around twofold increase in the tumor size suppression in the subcutaneous 4T1 tumor model than the fixed size nanoparticles. The increase in size led to increased residence time in the tumor tissue and improved the antitumor effect of size-changeable gold nanoparticles that increased with the coadministration of cediranib. In addition, celecoxib a cyclooxygenase-2 (COX-2) inhibitors also act as an angiogenesis inhibitor and result in vascular normalization and improved EPR effect in the tumor site [30]. The choice of therapy for vascular normalization must be chosen wisely since this approach is effective in delivering small-sized nanomedicines in comparison to the larger ones.
What the sources say
- Disputedcites [23] Carmeliet P. Jain R.K. Molecular mechanisms and clinical applications of angiogenesis Nature 2011 473 298 307 10.1038/nature10144 21593862 PMC4049445 sourceExperimental — accuracy not yet measured
The section ‘Clinical anti-angiogenesis with VEGF blockers’ says VEGF receptor TKIs are effective as monotherapy in certain cancers, although they fail in others. That directly contradicts the unqualified claim that antiangiogenic treatment has been proven ineffective when used alone in clinical settings. Page numbers were not provided in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The other mechanical pressures and physical barriers due to the rapid growth of tumor mass may also contribute to the heterogeneity of the EPR effect and declined efficiency of nanotherapeutics in human tumors [103].”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 4. Dynamics of the EPR Effect and Strategies to Improve the Therapeutic Effects of Nanomedicines by Using EPR Effect Enhancers > 4.1. Dynamics and Heterogeneity of Vascular Structures in Human Tumors
What the sources say
- Disputedcites [103] Maeda H. Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs Clin. Transl. Med. 2018 7 11 10.1186/s40169-018-0185-6 29541939 PMC5852245 sourceExperimental — accuracy not yet measured
In “Problems with cancer drug screening and safety in rats and mice” (page unavailable), the paper describes growth-induced physical pressure as an artifact of rapidly growing mouse tumors, not a feature comparable to human tumor growth. It says human tumors usually grow much more slowly. This runs contrary to the claim’s proposed rapid-growth pressure mechanism in human tumors; the passage does not assess its proposed effect on EPR heterogeneity. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Breast cancer tumors developed in mice were investigated by CA-MSI using Gadoteridol, revealing tumor margins and vasculature by localizing the contrast agents.”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 5. Applications of Advanced Imaging Technologies for Visualization and Quantification of EPR-Induced Nanomedicine Distribution in Tumors
What the sources say
- Not checked — no full text of the sourcecites [145] Tata A. Zheng J. Ginsberg H.J. Jaffray D.A. Ifa D.R. Zarrine-Afsar A. Contrast Agent Mass Spectrometry Imaging Reveals Tumor Heterogeneity Anal. Chem. 2015 87 7683 7689 10.1021/acs.analchem.5b01992 26138213 source
- Disputedcites [146] Abdelmoula W.M. Regan M.S. Lopez B.G.C. Randall E.C. Lawler S. Mladek A.C. Nowicki M.O. Marin B.M. Agar J.N. Swanson K.R. Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data Anal. Chem. 2019 91 6206 6216 10.1021/acs.analchem.9b00854 30932478 PMC6691508 sourceExperimental — accuracy not yet measured
The Materials and Methods and Results describe a mouse brain glioblastoma model studied with MALDI MSI and MRI after administration of erlotinib—not breast tumors investigated with Gadoteridol. The Results map drug and tumor-associated molecular signals but do not report localizing a contrast agent to reveal tumor margins or vasculature. Page numbers were not provided in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A recent study by Chan W.C.W et al. demonstrated that inter-endothelial gaps in tumors may not be responsible for the transport of nanodrugs into solid tumors [161].”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 7. Challenges of EPR-Based Drug Delivery into Solid Tumors
What the sources say
- Disputedcites [161] Golombek S.K. May J.-N. Theek B. Appold L. Drude N. Kiessling F. Lammers T. Tumor targeting via EPR: Strategies to enhance patient responses Adv. Drug Deliv. Rev. 2018 130 17 38 10.1016/j.addr.2018.07.007 30009886 PMC6130746 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says that wide openings in tumor blood vessels allow nanomedicines to leave the vessels. The Anti-angiogenic therapy section (page unavailable) specifically says that closing gaps between endothelial cells limits drug delivery. Rather than reporting the attributed finding, this source describes those gaps as a route for transport into tumors. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Contrary to the EPR mechanism, the frequency of the gaps on the endothelial lining in tumors is too low to account for the NP accumulation in the tumor site, which was observed by TEM analysis [161].”
§ Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis > 7. Challenges of EPR-Based Drug Delivery into Solid Tumors
What the sources say
- Disputedcites [161] Golombek S.K. May J.-N. Theek B. Appold L. Drude N. Kiessling F. Lammers T. Tumor targeting via EPR: Strategies to enhance patient responses Adv. Drug Deliv. Rev. 2018 130 17 38 10.1016/j.addr.2018.07.007 30009886 PMC6130746 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says abnormally wide tumor-vessel fenestrations allow nanomedicines to leave the bloodstream and, with absent lymphatic drainage, accumulate in tumors. The Principles of EPR section likewise describes vascular leakiness as a basis for tumor targeting. The paper does not report the claimed TEM finding that endothelial gaps are too infrequent to account for accumulation. (LLM, conf=0.83)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
88 more claims · 56 with their cited sources checked
Create a free account to see all 155 claims and to verify the 2 references still open.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Parveen, 2022, Investigation of Eutectic Mixtures of Fatty Acids as a Novel Construct for Temperature-Responsive Drug Delivery, Int. J. Nanomed., 17, 2413, 10.2147/IJN.S359664”
Cited work 10.2147/ijn.s359664 · retracted 2023-11-07 · notice 10.2147/ijn.s448407 · this paper published 2023-02-23
Citations
Cites
1 retracted
Parveen, F., Madni, A., Torchilin, V. P., Rehman, M., Jamshaid, T., Filipczak, N., Rai, N., Khan, M. M., & Khan, M. I. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s359664 · Cited by 13
Self-citationRetractedNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“, have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
MethodMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 1×
“In clinical settings, this approach has been proven to be ineffective when used alone [23].”
MethodAnalysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · cited 1×
“7% NPs that were administered systemically reach tumors [160].”
BackgroundRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationProgress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
Blom, J. W. (2005) · JAMA · doi:10.1001/jama.293.6.715 · Cited by 1,949
Mechanisms of Thrombus Formation
Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871 · cited 1×
“The HIF-1α gene is translated into the HIF-1α protein, which is allied with the stimulation of a series of genes that may worsen the tumor state [62].”
BackgroundThe entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732 · cited 1×
“Transcytosis is a metabolically active process that necessities endothelial cells to reorganize their cytoskeleton and cell membrane, involving vesicle formation transporting NPs through the cytoplasm [123,162].”
Background
Research works printed but not linked: 1
- Yin H. Liao L. Fang J. Enhanced Permeability and Retention (EPR) Effect Based Tumor Targeting: The Concept, Application and Prospect JSM Clin. Oncol. Res. 2014 2 1010
Cited by
Khan, M. S., Alqahtani, T., Shmrany, H. A., Gupta, G., Goh, K. W., Sahebkar, A., & Kesharwani, P. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214636 · Cited by 145
Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting
Spada, A., & Gerber‐Lemaire, S. (2025) · Nanomaterials · doi:10.3390/nano15030158 · Cited by 93
Shestovskaya, M. V., Luss, A. L., Si, B., Makarov, V. V., & Keskinov, A. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102406 · Cited by 60
Nanotechnology Driven Innovations in Modern Pharmaceutics: Therapeutics, Imaging, and Regeneration
Parvin, N., Aslam, M., Alam, M. N., & Mandal, T. K. (2025) · Nanomaterials · doi:10.3390/nano15221733 · Cited by 77
“Future research should focus on integrating EPR-based delivery with tumor microenvironment modulation and personalized approaches to maximize therapeutic outcomes [86].”
Graphene Quantum Dots from Natural Carbon Sources for Drug and Gene Delivery in Cancer Treatment
Osorio, H. M., Castillo-Solís, F., Barragán, S. Y., Rodríguez-Pólit, C., & González‐Pastor, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910539 · Cited by 49
“Also, these nanoscale vectors can remain at the tumor site given their enhanced permeability and retention (EPR) effect [17,18].”
BackgroundOvercoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition
Yoo, H., Kim, Y., Kim, J., Cho, H., & Kim, K. (2024) · Molecules · doi:10.3390/molecules29173994 · Cited by 54
“Furthermore, to optimize the EPR effect, nanoparticles can be utilized to regulate the tumor microenvironment (TME), including tumor blood vessels and blood flow [37,38].”
BackgroundMariano, S., Carata, E., Calcagnile, L., & Panzarini, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070932 · Cited by 46
Imran, H., Tang, Y., Wang, S., Yan, X., Liu, C., Guo, L., Wang, E., & Xu, C. (2023) · Molecules · doi:10.3390/molecules29010031 · Cited by 45
“An advanced therapeutic system was developed by the combination of all-trans retinoic acid (ATRA) with DOX to resolve metastasis and stemness [170].”
BackgroundRecent advances in poly(amino acids), polypeptides, and their derivatives in drug delivery
Yuan, H., Jiang, M., Fang, H., & Tian, H. (2025) · Nanoscale · doi:10.1039/d4nr04481a · Cited by 39
Hong, Y., Ma, W., Wang, M., & Wang, H.-H. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00057b · Cited by 35
Inorganic Nanoparticle Functionalization Strategies in Immunotherapeutic Applications
Mao, W., & Yoo, H. S. (2024) · Biomaterials Research · doi:10.34133/bmr.0086 · Cited by 33
“Systemic delivery is realized by intravenous injection, and efficient delivery can be achieved by active targeting that employs tumor-targeting molecules to anchor tumor sites or passive tumor accumulation is mediated by particle size and surface charge [193–195].”
BackgroundLee, Y., Kim, M., Kim, N., Byun, S., Seo, S., & Han, J. Y. (2025) · Applied Sciences · doi:10.3390/app152111599 · Cited by 37
Javid, H., Oryani, M. A., Rezagholinejad, N., Hashemzadeh, A., & Karimi‐Shahri, M. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00281d · Cited by 25
Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook
Gupta, V., Kumar, D., Gupta, S., Tanwar, R., Jaiswal, N. K., Islam, M. M., Singh, S., Choudhary, N., Gowri, S. S., Webster, T. J., et al. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s568254 · Cited by 36
“76 These integrative tools support the rational design and optimization of hybrid nanocarriers by predicting performance in heterogeneous and evolving tumor niches, accelerating the translation of precision nanomedicine.”
Liu, D., Lü, N., Zang, F., Lu, M., Zhang, J., Zhao, Y., Wan, H., Wang, M., Li, Q., Wang, F., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09387 · Cited by 21
Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy
Cardoso, V. M. D. O., Bistaffa, M. J., Sterman, R. G., de Lima, L. L. P., Toldo, G. S., Cancino‐Bernardi, J., & Zucolotto, V. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c16840 · Cited by 25
Wan, F., Wang, H., Gu, Y., Fan, G., Hou, S., Yu, J., Wang, M., He, F., & Tian, L. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202303502 · Cited by 21
Liu, Y., Li, Y., Shen, W., Li, M., Wang, W., & Jin, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1409163 · Cited by 17
Rajaram, J., Mende, L. K., & Kuthati, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091120 · Cited by 16
“The combination of natural PSs with nanoparticles has great potential in overcoming MDR [17,18].”
BackgroundZhu, H., Feng, R., Li, D., et al. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114479 · Cited by 16
Navaneeth, A. G., & Karthikeyan, S. (2024) · RSC Pharmaceutics · doi:10.1039/d3pm00027c · Cited by 20
Sitta, J., Carlo, F. D., Kirven, I. A., Tackett, B. J. H., Penfornis, P., Dobbins, G. C., Barbier, M. T., Valle, L. D., Larsen, C. T., Schutt, E. G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413697 · Cited by 16
“…such as ultrasound from a diagnostic-grade US machine that creates shockwaves that remodel the tumor microenvironment (TME) and enhance the permeability and retention (EPR) of the OVs in the targeted tissue [42], enhances drug biodistribution of the MB payload to tumor cells and has great promise.”
Mahmoud, A. M., & Deambrogi, C. (2025) · Applied Biosciences · doi:10.3390/applbiosci4010016 · Cited by 20
Recent advances in the nanoparticle-based targeted cancer treatment: A review
Uddin, H. M. W., Progoti, Q. R. M., Rahman, A. F. M. M., Osman, A. I., & Salem, K. S. (2025) · Next Bioengineering · doi:10.1016/j.nxbio.2025.100011 · Cited by 24
Moving beyond traditional therapies: the role of nanomedicines in lung cancer
Zhang, J., Li, Y., Guo, S., Zhang, W., Fang, B., & Wang, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1363346 · Cited by 26
“…this issue, there is a need to enhance EPR-based drug delivery by modifying tumor vasculature, angiogenesis, vascular structure, blood fl ow, etc. Subhan et al. (2023) utilized a combination therapy of angiogenesis inhibitors and chemotherapy to normalize the vascular system and enhance the…”
BackgroundRaza, M. A., Khatoon, N., Parveen, R., Nirisha, V., Thakur, Y., Thakur, Y., Lata, K. A., Shifana, A. S., Disouza, J., Saoji, S. D., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145145 · Cited by 14
Abdessalem, M. A., & Adham, S. A. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.056955 · Cited by 19
Cancer nanomedicine from a clinician-scientist perspective: Lessons and prospects
Gabizón, A. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113731 · Cited by 16
Advancements in lung cancer: molecular insights, innovative therapies, and future prospects
Pradhan, A., Pattnaik, G., Das, S., Acharya, B., & Patra, C. N. (2025) · Medical Oncology · doi:10.1007/s12032-025-02725-1 · Cited by 15
“Since tumors exhibit leaky vasculature, liposomes preferentially accumulate in cancerous tissues, leading to improved therapeutic outcomes [109].”
Ghaznavi, H., Rezaee, M., Reynoso, F. J., & Darafsheh, A. (2025) · Journal of Physics D Applied Physics · doi:10.1088/1361-6463/ae0e2d · Cited by 15
Nanomaterials in gene therapy and genome editing: challenges and emerging directions
Jiang, M., Zhang, K., Wang, Z., Gao, M., Su, S., He, J., Xu, H., Bo, Z., Jiang, Z., Zhang, C., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03895-w · Cited by 17
“However, viral vectors raised safety concerns: they can trigger unwanted immune reactions and sometimes integrate their genes in harmful ways (causing insertional mutations) [2].”
Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics
Urbano‐Gámez, J. D., Guzzi, C., Bernal, M., Solivera, J., Martínez-Zubiaurre, I., Caro, C., & García‐Martín, M. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105213 · Cited by 14
Shaikh, S., Chary, P. S., & Mehra, N. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01527 · Cited by 13
Tumor-responsive nanomedicines for cancer therapy: design principles and therapeutic advances
Liu, Y., Wang, Y., Gemingnuer, A., Wang, H., & Meng, X. (2025) · Biomedical Materials · doi:10.1088/1748-605x/adf387 · Cited by 10
Li, Y., Liu, P., Zhang, B., Chen, J., & Yan, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02014-3 · Cited by 11
“For example, the EPR effect exhibits significant heterogeneity across different tumor types and among patients with the same type of tumor [32].”
Emerging trends in NanoTheranostics: Integrating imaging and therapy for precision health care
Fahmy, H. M., Bayoumi, L., Helal, N. F., Mohamed, N. R. A., Emarh, Y., & Ahmed, A. M. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126057 · Cited by 11
Prospect of Gold Nanoparticles in Pancreatic Cancer
Yin, T., Han, J., Cui, Y., Shang, D., & Xiang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060806 · Cited by 10
“Moreover, events such as thrombosis, which decrease blood perfusion, can further modify the EPR effect [26].”
BackgroundUltra-small micelles together with UTMD enhanced the therapeutic effect of docetaxel on Glioblastoma
Mao, K., Jiang, Q., Jiang, Y., et al. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106468 · Cited by 7
Targeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide
Lingasamy, P., Tobi, A., Kurm, K., Tammik, O., & Teesalu, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-11299-x · Cited by 8
“Several pharmacological strategies have been employed to increase tumor vascular permeability and improve tumor delivery (e.g., drugs modulating tumor blood pressure, inflammatory cytokines, and bradykinin mediators) 24,25 .”
Advances in targeted therapeutics and smart delivery systems based on precision nano-oncology
Ma, J., Zhao, C. F., & Liu, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115946 · Cited by 9
Yakubu, J. Y., Tagit, O., & Pandey, A. V. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2619094 · Cited by 9
“Clinical analyses show that the phenomenon is inconsistent, varying significantly between patients and even within different regions of the same tumor [53].”
Zhang, J., Zha, M., Xiao, S., Filipczak, N., Yalamarty, S. S. K., Wu, X., Gong, C., & Li, X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s510514 · Cited by 7
Self-citationDwivedi, J., Wal, A., Seemab, M., Singh, A., Wal, P., Tiwari, M., Sharma, K. K., & Gasmi, A. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2698781 · Cited by 10
Liu, X., Guo, Y., Guo, Y., et al. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106004 · Cited by 5
Ziaei, S., Rashtbari, B., Azamat, J., & Erfan‐Niya, H. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2274977 · Cited by 6
“The EPR effect is based on the fact that tumor tissues have a leaky vasculature and poor lymphatic drainage, which results in the accumulation of macromolecules and nanoparticles in the tumor interstitium (Subhan et al., 2023).”
Sun, Z., & Li, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb01822b · Cited by 7
Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy
Kalra, J., Baker, J. H. E., Sun, X., Kyle, A. H., Minchinton, A. I., & Bally, M. B. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05428-9 · Cited by 6
“Investigators have reported that the EPR effect is heterogeneous and likely not relevant in all tumors [30, 31].”
BackgroundZhang, X., Zhang, X., Zhu, J., Li, T., Yang, L., Lei, L., Wu, F., He, B., & Cao, J. (2025) · ACS Nano · doi:10.1021/acsnano.4c16986 · Cited by 4
Applications of Nanobiotechnology in Medicine
Aebisher, D., Dynarowicz, K., Rudy, I., Rogóż, K., Bartusik‐Aebisher, D., & Kawczyk‐Krupka, A. (2026) · Life · doi:10.3390/life16020302 · Cited by 8
“These developments reflect a shift from viewing the EPR effect as a universal principle toward considering it as a context-dependent phenomenon that must be carefully evaluated in clinically relevant settings [29].”
Nanoparticle-enabled In Situ drug potency activation for enhanced tumor-specific therapy
Chen, Y., Liu, L., Li, M., Chen, X., Li, Y., Tao, J., & Deng, Y. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106989 · Cited by 5
Colloidal and Biological Characterization of Dual Drug-Loaded Smart Micellar Systems
Herman, H., Raţă, D. M., Cadinoiu, A. N., Atanase, L. I., & Hermenean, A. O. (2024) · Polymers · doi:10.3390/polym16091189 · Cited by 5
“The nanometric sizes of PMs are another serious advantage as they allow accumulation in highly vascularized areas, such as tumors, by the enhanced permeability and retention (EPR) effect [7,8].”
BackgroundRathod, N. V., & Mishra, S. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202502012 · Cited by 7
“Similarly, polymeric nanocarriers enhanced curcumin delivery in colon carcinoma models by improving tumor tissue retention and reducing systemic clearance [68].”
Kampaengsri, S., Yong, G. Y., Aryamueang, S., Ouengwanarat, B., Pewklang, T., Chansaenpak, K., Jitrapakdee, S., Kue, C. S., & Kamkaew, A. (2025) · Scientific Reports · doi:10.1038/s41598-024-83249-y · Cited by 3
Pareek, A., Modi, D., Kapoor, D. U., Prajapati, B. G., Fareed, M., & Alsaidan, O. A. (2026) · International Journal of Polymeric Materials · doi:10.1080/00914037.2025.2610712 · Cited by 5
“[68] Passive targeting relies on the unique characteristics of tumor vasculature, such as leaky blood vessels and poor lymphatic drainage, allowing nanocarriers to accumulate through the Enhanced Permeation and Retention (EPR) effect.”
Nanomedicine for colorectal cancer therapy by remodeling the immune microenvironment
Wu, Y., Su, Y., Wei, Y., Shui, M., Li, W., Yang, L., & Luo, K. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114915 · Cited by 6
Lin, F., Huang, H., Long, J., Liang, R., Huang, Y., & Luo, X. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115389 · Cited by 3
Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles
Wu, F., Gao, Y., J, Y., Wang, D., Zhang, S., Cheung, O. Y. H., Zhao, K., Lu, H., Chen, Q., Chen, Y., et al. (2026) · Journal of Functional Biomaterials · doi:10.3390/jfb17050207 · Cited by 3
“The intrinsic size of NPs and the distinct anatomical and pathophysiological anomalies of tumor vasculature, such as the EPR effect, are exploited by passive targeting [66,67].”
Liposomal nanotherapeutics for cancer treatment: Targeted delivery and immunotherapy
Butt, M. Z., Tariq, Z., Imran, M., Al-Eidan, A. A., Mahjabeen, S., Fatima, S., Din, G. U., Anjum, S., Sharif, E., & Ibrahim, W. N. (2026) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320261438337 · Cited by 4
Nanoparticles and Nanomaterials for Targeted Drug Delivery: An Updated Review
Aihiokhai, M. O., Orogu, J. O., Ali, A. B. M., Akpo, M. O., Imoni, C. A., Oviri, M. O., Asemota, F. O., Ohwofaraye, G., Edo, G. I., Yousif, E., et al. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-026-00589-z · Cited by 4
Ren, G., Ping, C., Dong, X., Jin, Q., Zhou, X., Niu, X., Han, J., Pan, F., Li, Q. Y., Wang, R., et al. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c04650 · Cited by 2
Szwed, M., Jost, T., Majka, E., Gharibkandi, N. A., Majkowska‐Pilip, A., Frey, B., Bilewicz, A., Fietkau, R., Gaipl, U. S., Marczak, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041574 · Cited by 3
Nano-immunotherapy: Merging immunotherapy precision with nanomaterial delivery
Hà, N. T. T., Menon, S., & Rivero‐Müller, A. (2025) · iScience · doi:10.1016/j.isci.2025.112319 · Cited by 4
Understanding Cancer Biology and Microenvironment
Saha, A. K., Mahlawat, P., Kumar, M., & Koralkar, N. V. (2025) · Series in bioengineering · doi:10.1007/978-981-95-0457-2_2 · Cited by 1
Rahman, M. M., & Rahman, M. M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108393 · Cited by 2
Alaysereen, A., Daoud, M. M. E., Alhoda, M. M. A. M. B., Zayer, A. H. A., & Deen, G. R. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070800 · Cited by 2
“These approaches collaborate to enhance the therapeutic effectiveness of nanomedicines through tumor targeting [14].”
Cho, U., Pu, J., Sharma, A., Song, J., You, J. H., Kim, Y., Im, P. W., Park, H. W., Moon, H. E., Myeong, H. S., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02736-0 · Cited by 2
“…nanoparticles bearing folate, transferrin, or antibody fragments have demonstrated substantially enhanced tumor cell uptake and therapeutic efficacy in preclinical models, and their performance is less sensitive to the stromal and vascular barriers that attenuate passive EPR [45, 53].”
Abramova, A. A., Rogachev, V. V., Baimler, I. V., Gudkov, S. V., & Varlamova, E. G. (2026) · Biological Trace Element Research · doi:10.1007/s12011-026-05288-y · Cited by 1
Hypobaric hypoxia exposure regulates tissue distribution of nanomedicine for enhanced cancer therapy
Ye, T., & Chen, Z. (2024) · Cancer Nanotechnology · doi:10.1186/s12645-024-00257-3 · Cited by 1
CCK Receptor Inhibition Reduces Pancreatic Tumor Fibrosis and Promotes Nanoparticle Delivery
Abraham, T., Armold, M., McGovern, C. O., Harms, J. F., Darok, M. C., Gigliotti, C. M., Adair, B. M., Gray, J. L., Kelly, D. F., Adair, J. H., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051024 · Cited by 1
Liposomes in Anticancer Strategies
Izbińska, P., Szlauer, W., & Obłąk, E. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947312894240930110609 · Cited by 1
An Introductory Review on Nanoparticles Based Treatment of Cancer
Hanif, N., Hussain, M., Raheem, M. A., Kamran, T., Malik, A., & Siddiqui, M. (2024) · doi:10.46431/mejast.2024.7105 · Cited by 1
Popova, T. V., Van, M., Kurochkin, T. N., Tsyrempilov, S. A., Zakharova, O. D., Silnikov, V. N., & Godovikova, T. S. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025010194
Inose, T., Nakamura, M., Wang, X., & Oyane, A. (2025) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2025.136940 · Cited by 2
Development of radiolabeled 111In-albumin liposomes for long-term imaging of tumors
Ahrari, M., Saberi, Z., Abbasi, A., et al. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06446-4
Advancing Biomedical Innovations: A Review of Magnetic Nanoparticles
Singh, V., Rana, S., Rathaur, P., et al. (2025) · Nanoscience & Nanotechnology-Asia · doi:10.2174/0122106812387110250714094126
Venkatesan, K. B., Alamelu, S., Srinivasan, M. K., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04873-7
Shahriari, M. H., Shaban, M., Salmani, H., Malek-Khatabi, A., Salehi, Z., & Akrami, M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108201 · Cited by 1
Dhasmana, A., Preetam, S., Santhanam, A., Rautela, I., Sati, A., Bora, J., Rajak, B. K., Singh, N., & Malik, S. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-026-02056-6
“Moreover, recent reviews highlight that nanocarriers capable of adapting their size post-administration either through matrix relaxation or drug diffusion may outperform static systems in achieving deep tumor penetration [ 40].”
Muteeb, G., Elsharkawy, R. S., El-Gouhari, A. H., Alghuwainem, G. Y., Aatif, M., & Khafaga, D. S. R. (2026) · Micro & Nano Letters · doi:10.1049/mna2.70020
Functionalization Approaches: FA/HA Coating and Targeted Cancer Delivery
Gulia, S., Thakur, M., & Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-8165-8_10
Nanosystems to Improve the Delivery of Biologicals
Raza, A., & Wu, W. (2025) · Springer handbooks · doi:10.1007/978-3-032-01636-2_7
Polymeric micelles as versatile shuttles: Strategic approaches for glioblastoma-targeted delivery
Verma, M., Kumar, A., Kanaujiya, S., Subhashchandra, G. K., Mittal, K., & Rajinikanth, P. S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108622
Dubbert, J., Kunkel, F., Mühlenberg, T., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00129
Prospects of DNA nanotechnology in stroke repair and regeneration
Kansara, K., Jantrania, K., Chokshi, S., Bhatia, D. D., & Kumar, A. (2026) · Communications Biology · doi:10.1038/s42003-026-10617-x
“Chan W.C.W et al, found only 0.7% of NPs are able to reach tumor showcasing the inef fi ciency of EPR (enhanced permeability and retention) based drug delivery 134,135 .”
InfluentialEngineering calcium-based nanoparticles for cancer treatment
Costa, M., Carvalho, B., Sousa, Â., Valente, J. F. A., & Patrício, T. M. F. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115974
Sharma, A., Mishra, A. K., Mathur, P., Singh, R. P., & Rani, L. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00613-1
“As Kesharwani et al. [67] and Subhan et al. [121] emphasize, passive targeting alone is unlikely to achieve transformative outcomes in TNBC. Future PLGA designs should either incorporate EPR-enhancing physical co-treatments (e.g., ultrasound, radiation) or transition to active/stimuli-responsive…”
Kah, G., & Abrahamse, H. (2026) · RSC Advances · doi:10.1039/d6ra03514k · Cited by 1
Wang, X., Mi, H., Ren, H., et al. (2026) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2026.111233
Li, B., Wang, Y., Lin, Z., Wang, X., Fu, Z., Guo, B., Xu, Y., Chen, J., Ding, B., & Wu, X. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103006
Alyami, H. S., & Ahmadi, N. A. (2026) · Medicine · doi:10.1097/md.0000000000050490
“[22,23] As Figure 4 illustrates, these drug delivery strategies are mediated by NPs, including active ligand-based targeting and passive accumulation via the EPR effect.”
Preparation of multifunctional protein-capped selenium nanoparticles for drug delivery
Saeed, A., Munawar, A., Khan, I. U., et al. (2026) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-026-11103-8
Singaravelu, S., Balu, R., Senthilkumar, C., & Jayaprakash, J. (2026) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2026.1912922
Overhoff, J., Sanin, A. Y., Demir, B., Koch, J. P., Wartmann, T., Busse, M., Fachet, M., Hoeschen, C., Hacker, M. C., Kahlert, U. D., et al. (2026) · Materials Advances · doi:10.1039/d6ma01025c
Decoding the uptake pathway of nanoparticles in tumor cells: mechanisms, developments and challenges
Chen, Z., Zhou, L., Li, S., & Zhang, X. (2026) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2026.104054 · Cited by 1
Shaikh, S. A., Mishra, A., & Havelikar, U. A. (2026) · Biomedical Analysis · doi:10.1016/j.bioana.2026.09.001
Metadata
- Authors
- Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2023-02-23
- Volume
- 13
- Issue
- 3
- Pages
- 389
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC10051487
- OpenAlex
- W4321601715
- Cited by
- 98
- References
- 167
- Citations by year
- 2026: 34 · 2025: 33 · 2024: 26 · 2023: 5
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor microenvironment, nanomedicine, anticancer drug delivery, tumor targeting, tumor imaging, animal models, clinical translation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.